“The value of the approach has been proven,” claims AbbVie regulatory policy head
The EU should adopt a “dynamic” approach to assessing potential new drugs, a sector leader has suggested.
Under dynamic regulatory assessment, regulators would look at partial data on drug safety and efficacy as the data are generated, rather than waiting for complete data as at present.
This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com
Pivot-RP users can log in and view the article via this link.